Elacestrant 86mg Tablets

Elacestrant 86mg Tablets represent a significant innovation in the endocrine treatment of breast cancer, functioning as an oral Selective Estrogen Receptor Degrader (SERD). Unlike Traditional hormonal therapies that merely block estrogen from binding to its receptor, Elacestrant has a dual mechanism of action. It functions as a potent antagonist, blocking the receptor’s signaling capacity, and simultaneously induces a conformational change that targets the estrogen receptor (ERα) for degradation by the cell’s waste disposal machinery.

This degradation capability is particularly crucial in the context of resistance. A common mechanism by which breast cancer becomes resistant to standard aromatase inhibitors is through the acquisition of mutations in the ESR1 gene (the gene encoding the estrogen receptor). These mutations can cause the receptor to remain permanently “on” even without estrogen. Elacestrant 86mg Tablets are specifically engineered to bind to these mutated receptors and degrade them, effectively shutting down the survival signal that the cancer cells depend on.

Indications / Uses of Elacestrant 86mg Tablets

Elacestrant 86mg Tablets are indicated for the treatment of postmenopausal women or adult men with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), advanced or metastatic breast cancer. Specific clinical contexts include:

• ESR1-Mutated Disease: It is the first therapy specifically indicated for patients whose tumors harbor an ESR1 mutation, as detected by an FDA-approved diagnostic test.
• Post-Progression Therapy: Indicated for patients who have experienced disease progression following at least one line of endocrine therapy (such as letrozole or anastrozole), often in the metastatic setting.
• Dose Management: The 86mg strength is frequently used for dose adjustments. While the standard starting dose may be higher (345mg), the 86mg tablet allows for precise titration down to 258mg, 172mg, or 86mg to manage adverse reactions while maintaining therapeutic suppression.

Key Features

• First Oral SERD: Unlike fulvestrant, which is a SERD requiring painful intramuscular injections, Elacestrant provides the potency of receptor degradation in a convenient oral tablet.
• Targets Ligand-Independent Signaling: By degrading the receptor, it is effective even against constitutively active ESR1 mutations that render other hormonal drugs ineffective.
• Once-Daily Dosing: The medication is taken once daily with food, simplifying the regimen for patients undergoing long-term cancer care.
• Survival Benefit: Clinical trials (EMERALD) demonstrated a statistically significant improvement in progression-free survival (PFS) specifically in the population with ESR1 mutations compared to standard-of-care endocrine therapy.

Storage for Elacestrant 86mg Tablets

To maintain the stability and efficacy of Elacestrant 86mg Tablets, proper storage is required. Store the medication at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Brief excursions are permitted between 15°C and 30°C (59°F to 86°F). Keep the tablets in their original bottle to protect them from light and moisture. Do not transfer them to a pill organizer unless necessary, as the original packaging is designed to ensure stability. Keep the container tightly closed and out of the reach and sight of children and pets.

Important Note on Elacestrant 86mg Tablets

Treatment with Elacestrant 86mg Tablets requires monitoring for specific side effects. Dyslipidemia (abnormal cholesterol and triglyceride levels) has been observed; lipid profiles should be monitored prior to starting and periodically during treatment.

Gastrointestinal distress, particularly nausea and vomiting, is common. Patients should be advised to take the medication with food to improve tolerability and absorption. Antiemetic prophylaxis may be considered for patients with persistent nausea.

The drug can cause embryo-fetal toxicity. It is not recommended for use during pregnancy, and females of reproductive potential should use effective non-hormonal contraception during treatment and for one week after the final dose.

Elacestrant is a substrate of CYP3A4. Concomitant use with strong or moderate CYP3A4 inducers (e.g., rifampin, phenytoin) should be avoided as they can significantly decrease drug levels and efficacy. Strong CYP3A4 inhibitors may increase drug exposure. Always review your full medication list with your oncologist.